|
JPS5663950A
(en)
|
1979-10-30 |
1981-05-30 |
Mitsubishi Chem Ind Ltd |
Cyclopropanecarboxylic ester
|
|
FR2535721A1
(fr)
|
1982-11-08 |
1984-05-11 |
Sanofi Sa |
Derives de la piperidinedione protecteurs du myocarde presentant une acticite antiarythmique, leur procede de preparation et les medicaments qui contiennent lesdits derives
|
|
JPH021450Y2
(https=)
|
1984-09-27 |
1990-01-16 |
|
|
|
US4911920A
(en)
|
1986-07-30 |
1990-03-27 |
Alcon Laboratories, Inc. |
Sustained release, comfort formulation for glaucoma therapy
|
|
FR2588189B1
(fr)
|
1985-10-03 |
1988-12-02 |
Merck Sharp & Dohme |
Composition pharmaceutique de type a transition de phase liquide-gel
|
|
CA2018801C
(en)
|
1990-06-12 |
2000-08-22 |
Pierre Louis Beaulieu |
Antiherpes peptide derivatives having a 1,4-dioxo c n-terminus
|
|
JPH04177244A
(ja)
|
1990-11-10 |
1992-06-24 |
Konica Corp |
ハロゲン化銀写真感光材料
|
|
CA2033447C
(en)
|
1990-12-31 |
1999-08-31 |
Robert Deziel |
Synergistic combination for treating herpes infections
|
|
JP2594486B2
(ja)
|
1991-01-15 |
1997-03-26 |
アルコン ラボラトリーズ インコーポレイテッド |
局所的眼薬組成物
|
|
US5212162A
(en)
|
1991-03-27 |
1993-05-18 |
Alcon Laboratories, Inc. |
Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
|
|
JPH05301838A
(ja)
|
1991-10-15 |
1993-11-16 |
Mitsubishi Kasei Corp |
スチレン誘導体
|
|
US5792771A
(en)
|
1992-11-13 |
1998-08-11 |
Sugen, Inc. |
Quinazoline compounds and compositions thereof for the treatment of disease
|
|
WO1995024190A2
(en)
|
1994-03-07 |
1995-09-14 |
Sugen, Inc. |
Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof
|
|
JPH0827090A
(ja)
|
1994-05-13 |
1996-01-30 |
Sumitomo Chem Co Ltd |
シアノ酢酸アミド誘導体、その用途およびその製造中間体
|
|
US6331555B1
(en)
|
1995-06-01 |
2001-12-18 |
University Of California |
Treatment of platelet derived growth factor related disorders such as cancers
|
|
DE59808284D1
(de)
|
1997-03-14 |
2003-06-12 |
Basf Ag |
Cycloalkylalkancarbonsäureamide, deren herstellung und verwendung
|
|
US7863444B2
(en)
|
1997-03-19 |
2011-01-04 |
Abbott Laboratories |
4-aminopyrrolopyrimidines as kinase inhibitors
|
|
IL125947A0
(en)
|
1997-09-17 |
1999-04-11 |
American Cyanamid Co |
3-(1,2-benzisothiazol- and isoxazol-5-yl)-2,4(1h,3h)-pyrimidinedione or thione and 3-(1,2-benzisothiazol- and isoxazol-5-yl)-4(3)-pyrimidinone or thione herbicidal agents
|
|
JP2001519379A
(ja)
|
1997-10-09 |
2001-10-23 |
ペリオ、プロダクツ、リミテッド |
遅延性総放出胃腸薬物送達システム
|
|
US6713474B2
(en)
|
1998-09-18 |
2004-03-30 |
Abbott Gmbh & Co. Kg |
Pyrrolopyrimidines as therapeutic agents
|
|
EP1169038B9
(en)
|
1999-04-15 |
2013-07-10 |
Bristol-Myers Squibb Company |
Cyclic protein tyrosine kinase inhibitors
|
|
JP2003509428A
(ja)
|
1999-09-17 |
2003-03-11 |
アボツト・ゲー・エム・ベー・ハー・ウント・コンパニー・カーゲー |
治療薬としてのピラゾロピリミジン
|
|
AU2000240570A1
(en)
|
2000-03-29 |
2001-10-08 |
Knoll Gesellschaft Mit Beschraenkter Haftung |
Pyrrolopyrimidines as tyrosine kinase inhibitors
|
|
AR042586A1
(es)
|
2001-02-15 |
2005-06-29 |
Sugen Inc |
3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la protein quinasa; sus composiciones farmaceuticas; un metodo para la modulacion de la actividad catalitica de la proteinquinasa; un metodo para tratar o prevenir una afeccion relacionada con la proteinquinasa
|
|
MXPA03008560A
(es)
|
2001-03-22 |
2004-06-30 |
Abbot Gmbh & Co Kg |
Pirazolopirimidinas como agentes terapeuticos.
|
|
CA2465328C
(en)
|
2001-11-01 |
2011-06-14 |
Michael Francis Gross |
Piperidines
|
|
JP3991812B2
(ja)
|
2001-12-11 |
2007-10-17 |
住友化学株式会社 |
エステル化合物およびその用途
|
|
WO2003068157A2
(en)
|
2002-02-11 |
2003-08-21 |
The Brigham And Women's Hospital, Inc. |
Kinase inhibitors and methods of use thereof
|
|
NI200300043A
(es)
|
2002-03-28 |
2003-11-05 |
Warner Lambert Co |
AMINOACIDOS CON AFINIDAD POR LA PROTEINA a2DELTA.
|
|
FR2842735B1
(fr)
|
2002-07-26 |
2006-01-06 |
Flamel Tech Sa |
Microcapsules a liberation modifiee de principes actifs peu solubles pour l'administration per os
|
|
GB0219024D0
(en)
|
2002-08-15 |
2002-09-25 |
Pfizer Ltd |
Synergistic combinations
|
|
US7419981B2
(en)
|
2002-08-15 |
2008-09-02 |
Pfizer Inc. |
Synergistic combinations of an alpha-2-delta ligand and a cGMP phosphodieterse 5 inhibitor
|
|
GB0226370D0
(en)
|
2002-11-12 |
2002-12-18 |
Novartis Ag |
Organic compounds
|
|
MXPA05008878A
(es)
|
2003-02-21 |
2005-10-05 |
Pfizer |
Derivados de aminotiazol sustituidos con cicloalquilo que contiene n y composiciones farmaceuticas para inhibir la proliferacion celular, y metodos para su uso.
|
|
WO2004100868A2
(en)
|
2003-04-23 |
2004-11-25 |
Abbott Laboratories |
Method of treating transplant rejection
|
|
WO2005011812A1
(en)
|
2003-08-01 |
2005-02-10 |
Chugai Seiyaku Kabushiki Kaisha |
Cyanoamide compounds useful as malonyl-coa decarboxylase inhibithors
|
|
MXPA06002455A
(es)
|
2003-09-02 |
2006-08-31 |
Pfizer Prod Inc |
Formas de dosificacion de liberacion sostenida de ziprasidona.
|
|
WO2005023773A1
(en)
|
2003-09-04 |
2005-03-17 |
Pfizer Limited |
Process for the preparation of substituted aryl pyrazoles
|
|
GB0322140D0
(en)
|
2003-09-22 |
2003-10-22 |
Pfizer Ltd |
Combinations
|
|
CA2539976A1
(en)
|
2003-09-25 |
2005-04-07 |
Warner-Lambert Company Llc |
Therapeutic beta aminoacids
|
|
JP2007520559A
(ja)
|
2004-02-03 |
2007-07-26 |
アボット・ラボラトリーズ |
治療薬としてのアミノベンゾオキサゾール類
|
|
JP4552456B2
(ja)
|
2004-02-27 |
2010-09-29 |
住友化学株式会社 |
エステル化合物およびその用途
|
|
JPWO2005085210A1
(ja)
|
2004-03-10 |
2008-01-17 |
小野薬品工業株式会社 |
ニトリル化合物およびその化合物を有効成分として含有する医薬組成物
|
|
US7807719B2
(en)
|
2004-09-14 |
2010-10-05 |
Chaim Roifman |
Compounds useful for modulating abnormal cell proliferation
|
|
JP2008514635A
(ja)
|
2004-09-27 |
2008-05-08 |
コーザン バイオサイエンシス インコーポレイテッド |
特異的キナーゼ阻害剤
|
|
AU2006213746A1
(en)
|
2005-02-11 |
2006-08-17 |
Coley Pharmaceutical Group, Inc. |
Oxime and hydroxylamine substituted imidazo(4,5-c) ring compounds and methods
|
|
WO2006103661A2
(en)
|
2005-03-28 |
2006-10-05 |
Dexcel Pharma Technologies Ltd. |
Controlled absorption of statins in the intestine
|
|
CA2618646A1
(en)
|
2005-06-03 |
2007-11-15 |
Xenon Pharmaceuticals Inc. |
Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors
|
|
US20070149464A1
(en)
|
2005-06-15 |
2007-06-28 |
Pfizer Inc. |
Combination
|
|
US7645786B2
(en)
|
2005-06-15 |
2010-01-12 |
Pfizer Inc. |
Substituted arylpyrazoles
|
|
US20080176865A1
(en)
|
2005-06-15 |
2008-07-24 |
Pfizer Limited |
Substituted arylpyrazoles
|
|
US20080146643A1
(en)
|
2005-06-15 |
2008-06-19 |
Pfizer Limited |
Combination
|
|
CN101228134A
(zh)
|
2005-06-15 |
2008-07-23 |
辉瑞有限公司 |
用作杀寄生虫剂的取代芳基吡唑
|
|
GB0517205D0
(en)
|
2005-08-22 |
2005-09-28 |
Novartis Ag |
Organic compounds
|
|
JP5222561B2
(ja)
|
2005-10-07 |
2013-06-26 |
キッセイ薬品工業株式会社 |
含窒素芳香族複素環化合物およびそれを含有する医薬組成物
|
|
WO2007064932A2
(en)
|
2005-12-02 |
2007-06-07 |
Bayer Healthcare Llc. |
Pyrrolotriazine derivatives useful for treating cancer through inhibition of aurora kinase
|
|
KR20080098490A
(ko)
|
2006-01-13 |
2008-11-10 |
파마시클릭스, 인코포레이티드 |
티로신 키나제 억제제 및 이의 용도
|
|
RU2456265C2
(ru)
|
2006-03-31 |
2012-07-20 |
Дзе Борд Оф Риджентс Оф Дзе Юниверсити Оф Техас Систем |
Биологически доступная для перорального применения кофейная кислота, относящаяся к противоопухолевым лекарственным средствам
|
|
US7645748B2
(en)
|
2006-04-03 |
2010-01-12 |
Forbes Medi-Tech Inc. |
Sterol/stanol phosphorylnitroderivatives and use thereof
|
|
EP2700638A1
(en)
|
2006-05-31 |
2014-02-26 |
The Regents Of the University of California |
Purine analogs
|
|
US20100292229A1
(en)
|
2006-06-30 |
2010-11-18 |
The Board Of Regents Of The University Of Texas System |
Tryphostin-analogs for the treatment of cell proliferative diseases
|
|
ATE523499T1
(de)
|
2006-07-06 |
2011-09-15 |
Array Biopharma Inc |
Cyclopenta [d]-pyrimidine als akt-proteinkinasehemmer
|
|
DK2526933T3
(en)
|
2006-09-22 |
2015-05-18 |
Pharmacyclics Inc |
Inhibitors of Bruton's tyrosine kinase
|
|
CA2668286C
(en)
|
2006-11-03 |
2014-09-16 |
Pharmacyclics, Inc. |
Bruton's tyrosine kinase activity probe and method of using
|
|
KR20090086080A
(ko)
|
2006-11-23 |
2009-08-10 |
노파르티스 아게 |
피리미딘 및 그의 ｃｘｃｒ2 수용체 길항제로서의 용도
|
|
CN101730699A
(zh)
|
2007-03-21 |
2010-06-09 |
百时美施贵宝公司 |
可用于治疗增殖性、变应性、自身免疫性和炎症性疾病的稠合杂环化合物
|
|
GB2447933A
(en)
|
2007-03-27 |
2008-10-01 |
Chemence Ltd |
Cyanoacrylate monomer for forming an adhesive polymer
|
|
SG10202107066WA
(en)
|
2007-03-28 |
2021-07-29 |
Pharmacyclics Llc |
Inhibitors of bruton's tyrosine kinase
|
|
CA2712507A1
(en)
|
2008-02-25 |
2009-09-03 |
F. Hoffmann-La Roche Ag |
Pyrrolopyrazine kinase inhibitors
|
|
JP5368485B2
(ja)
|
2008-02-25 |
2013-12-18 |
エフ．ホフマン−ラ ロシュ アーゲー |
ピロロピラジンキナーゼインヒビター
|
|
KR101324804B1
(ko)
|
2008-05-13 |
2013-11-01 |
아이알엠 엘엘씨 |
키나제 억제제로서의 질소 함유 융합 헤테로사이클 및 그의 조성물
|
|
CA2724715A1
(en)
|
2008-05-22 |
2009-11-26 |
Amgen Inc. |
Heterocycles as protein kinase inhibitors
|
|
CA2730930C
(en)
|
2008-07-16 |
2015-01-13 |
Pharmacyclics, Inc. |
Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors
|
|
JP2011529918A
(ja)
|
2008-08-01 |
2011-12-15 |
バイオクライスト ファーマシューティカルズ， インコーポレイテッド |
Ｊａｋ３阻害剤としてのピペリジン誘導体
|
|
US8450337B2
(en)
|
2008-09-30 |
2013-05-28 |
Moleculin, Llc |
Methods of treating skin disorders with caffeic acid analogs
|
|
US20120028981A1
(en)
|
2008-11-05 |
2012-02-02 |
Principia Biopharma Inc. |
Kinase Knockdown Via Electrophilically Enhanced Inhibitors
|
|
US20100113520A1
(en)
|
2008-11-05 |
2010-05-06 |
Principia Biopharma, Inc. |
Kinase knockdown via electrophilically enhanced inhibitors
|
|
US8426428B2
(en)
|
2008-12-05 |
2013-04-23 |
Principia Biopharma, Inc. |
EGFR kinase knockdown via electrophilically enhanced inhibitors
|
|
JP2013504325A
(ja)
|
2009-09-09 |
2013-02-07 |
アビラ セラピューティクス， インコーポレイテッド |
Ｐｉ３キナーゼインヒビターおよびその使用
|
|
US7718662B1
(en)
|
2009-10-12 |
2010-05-18 |
Pharmacyclics, Inc. |
Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase
|
|
US20130035325A1
(en)
|
2009-11-16 |
2013-02-07 |
The Regents Of The University Of California |
Kinase inhibitors
|
|
MX2012013378A
(es)
|
2010-05-20 |
2013-01-24 |
Hoffmann La Roche |
Derivados de pirrolo [2, 3-b] pirazina-7-carboxamida y sus uso como inhibidores de cinasa janus (jak) y cinasa tirosina del brazo (syk).
|
|
TWI500617B
(zh)
|
2010-05-31 |
2015-09-21 |
Ono Pharmaceutical Co |
Purine ketone derivatives
|
|
US20120071497A1
(en)
|
2010-06-03 |
2012-03-22 |
Pharmacyclics, Inc. |
Methods of treating abc-dlbcl using inhibitors of bruton's tyrosine kinase
|
|
CA3007787C
(en)
|
2010-06-03 |
2020-03-10 |
Pharmacyclics Llc |
The use of inhibitors of bruton's tyrosine kinase (btk)
|
|
CN101880243A
(zh)
|
2010-06-04 |
2010-11-10 |
贵阳柏丝特化工有限公司 |
一种含氟氰拟除虫菊酯化合物及其合成方法与用途
|
|
MX336875B
(es)
|
2010-08-10 |
2016-02-04 |
Celgene Avilomics Res Inc |
Sal de besilato de un inhibidor de tirosina cinasa de bruton (btk).
|
|
EP2635284B1
(en)
*
|
2010-11-01 |
2019-12-18 |
Celgene CAR LLC |
Heterocyclic compounds and uses thereof
|
|
US20140107151A1
(en)
|
2011-05-17 |
2014-04-17 |
Principia Biophama Inc. |
Tyrosine kinase inhibitors
|
|
WO2012158795A1
(en)
|
2011-05-17 |
2012-11-22 |
Principia Biopharma Inc. |
Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors
|
|
PL2710005T3
(pl)
|
2011-05-17 |
2017-07-31 |
Principia Biopharma Inc. |
Inhibitory kinazy tyrozynowej
|
|
ES2770550T3
(es)
|
2011-05-17 |
2020-07-02 |
Univ California |
Inhibidores de quinasa
|
|
US8828426B2
(en)
|
2011-06-07 |
2014-09-09 |
Zx Pharma, Llc |
Multiparticulate L-carnitine compositions and related methods
|
|
MX2014000130A
(es)
|
2011-06-28 |
2014-05-01 |
Pharmacyclics Inc |
Procedimientos y composiciones para la inhibicion de resorcion osea.
|
|
JP2014520863A
(ja)
|
2011-07-13 |
2014-08-25 |
ファーマサイクリックス，インク． |
Ｂｒｕｔｏｎ型チロシンキナーゼの阻害剤
|
|
EP2548877A1
(en)
|
2011-07-19 |
2013-01-23 |
MSD Oss B.V. |
4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors
|
|
EP3689878B1
(en)
|
2011-07-19 |
2021-10-06 |
Merck Sharp & Dohme B.V. |
4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as btk-inhibitors
|
|
CA2841887A1
(en)
|
2011-07-19 |
2013-01-24 |
Merck Sharp & Dohme B.V. |
4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as btk - inhibitors
|
|
CN103874699A
(zh)
|
2011-09-20 |
2014-06-18 |
赛尔佐姆有限公司 |
吡唑并[4,3-c]吡啶衍生物作为激酶抑制剂
|
|
MX391121B
(es)
|
2011-10-19 |
2025-03-19 |
Pharmacyclics Llc |
Uso de inhibidores de la tirosina cinasa de bruton (btk).
|
|
US8377946B1
(en)
|
2011-12-30 |
2013-02-19 |
Pharmacyclics, Inc. |
Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
|
|
US8501724B1
(en)
|
2012-01-31 |
2013-08-06 |
Pharmacyclics, Inc. |
Purinone compounds as kinase inhibitors
|
|
KR20210033067A
(ko)
|
2012-06-04 |
2021-03-25 |
파마싸이클릭스 엘엘씨 |
브루톤 타이로신 키나아제 저해제의 결정 형태
|
|
US9353087B2
(en)
|
2012-06-08 |
2016-05-31 |
Biogen Ma Inc. |
Inhibitors of Bruton's tyrosine kinase
|
|
WO2013191965A1
(en)
|
2012-06-18 |
2013-12-27 |
Principia Biopharma Inc. |
Reversible covalent pyrrolo- or pyrazolopyrimidines useful for the treatment cancer and autoimmune diseases
|
|
US20150140085A1
(en)
|
2012-06-29 |
2015-05-21 |
Principia Biopharma Inc. |
Formulations comprising ibrutinib
|
|
WO2014016754A2
(en)
|
2012-07-26 |
2014-01-30 |
Lupin Limited |
Pharmaceutical compositions of proton pump inhibitor
|
|
WO2014022569A1
(en)
|
2012-08-03 |
2014-02-06 |
Principia Biopharma Inc. |
Treatment of dry eye
|
|
SI2892900T1
(en)
|
2012-09-10 |
2018-01-31 |
Principia Biopharma Inc. |
Pyrazolopyrimidine compounds as kinase inhibitors
|
|
TW201427664A
(zh)
|
2012-11-02 |
2014-07-16 |
Pharmacyclics Inc |
Ｔｅｃ家族激酶抑制劑佐劑療法
|
|
KR101668574B1
(ko)
|
2012-11-02 |
2016-10-24 |
화이자 인코포레이티드 |
브루톤 티로신 키나제 억제제
|
|
EA201590855A1
(ru)
|
2012-11-15 |
2015-11-30 |
Фармасайкликс, Инк. |
Соединения пирролопиримидина как ингибиторы киназ
|
|
US20140142099A1
(en)
|
2012-11-20 |
2014-05-22 |
Principia Biopharma Inc. |
Purinone Derivatives as Tyrosine Kinase Inhibitors
|
|
CN105007940B
(zh)
|
2012-12-20 |
2017-08-25 |
宾夕法尼亚州研究基金会 |
与癌症治疗相关的方法和组合物
|
|
JO3377B1
(ar)
|
2013-03-11 |
2019-03-13 |
Takeda Pharmaceuticals Co |
مشتقات بيريدينيل وبيريدينيل مندمج
|
|
US8957080B2
(en)
|
2013-04-09 |
2015-02-17 |
Principia Biopharma Inc. |
Tyrosine kinase inhibitors
|
|
JPWO2014171542A1
(ja)
|
2013-04-19 |
2017-02-23 |
武田薬品工業株式会社 |
放出制御製剤
|
|
WO2015132799A2
(en)
|
2014-02-03 |
2015-09-11 |
Cadila Healthcare Limited |
Novel heterocyclic compounds
|
|
CN112353806A
(zh)
|
2014-02-21 |
2021-02-12 |
普林斯匹亚生物制药公司 |
Btk抑制剂的盐和固体形式
|
|
SG11201704808VA
(en)
|
2014-12-18 |
2017-07-28 |
Principia Biopharma Inc |
Treatment of pemphigus
|
|
US20180193274A1
(en)
|
2014-12-24 |
2018-07-12 |
Principia Biopharma Inc. |
Compositions for ileo-jejunal drug delivery
|
|
PT3236953T
(pt)
|
2014-12-24 |
2021-01-29 |
Principia Biopharma Inc |
Dosagem específica de sítio de um inibidor de btk
|
|
UA124090C2
(uk)
|
2015-06-03 |
2021-07-21 |
Прінсіпіа Байофарма Інк. |
Інгібітори тирозинкінази
|
|
WO2016210165A1
(en)
|
2015-06-24 |
2016-12-29 |
Principia Biopharma Inc. |
Tyrosine kinase inhibitors
|
|
CN105753863B
(zh)
|
2015-09-11 |
2018-07-31 |
东莞市真兴贝特医药技术有限公司 |
氧代二氢咪唑并吡啶类化合物及其应用
|
|
EP3414234B1
(en)
|
2015-10-14 |
2022-06-29 |
Zibo Biopolar Changsheng Pharmaceutical Co. Ltd. |
Bruton's tyrosine kinase inhibitors
|
|
CN115054586B
(zh)
|
2016-06-29 |
2024-08-02 |
普林斯匹亚生物制药公司 |
改性的释放制剂
|
|
WO2019208805A1
(ja)
|
2018-04-27 |
2019-10-31 |
小野薬品工業株式会社 |
Ｂｔｋ阻害活性を有する化合物を有効成分として含む自己免疫疾患の予防および／または治療剤
|
|
CN110483521B
(zh)
|
2018-05-14 |
2022-06-07 |
杭州和正医药有限公司 |
一种可逆共价布鲁顿酪氨酸激酶抑制剂、药物组合物及其应用
|
|
US20210106584A1
(en)
|
2019-10-14 |
2021-04-15 |
Principia Biopharma Inc. |
Methods for treating immune thrombocytopenia by administering (r)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile
|
|
US11814390B2
(en)
|
2020-01-22 |
2023-11-14 |
Principia Biopharma Inc. |
Crystalline forms of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)-1H-pyrazolo[3,4-D]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile
|
|
WO2022081512A1
(en)
|
2020-10-12 |
2022-04-21 |
Synubi Pharmaceuticals Llc |
Compositions and methods of treatment of neuroinflammatory diseases with bruton's tyrosine kinase inhibitors
|
|
KR20250088633A
(ko)
|
2022-10-31 |
2025-06-17 |
프린시피아 바이오파마, 인코퍼레이티드 |
(R)-2-[3-[4-아미노-3-(2-플루오로-4-페녹시-페닐)피라졸로[3,4-d]피리미딘-1-일]피페리딘-1-카르보닐]-4-메틸-4-[4-(옥세탄-3-일)피페라진-1-일]펜트-2-엔니트릴을투여하여 면역 혈소판 감소증을 치료하는 방법
|